

Supplemental Digital Content 1. Comparisons Evaluating Heterosubtypic, Heterotypic, and Homosubtypic Immunity

Study (Age)	Placebo Recipients, n	Seasons, Location	Year 1 Illness	Year 2 Illness	Incidence in Year 2	RR (95% CI)
<i>Heterosubtypic Immunity</i>						
Vesikari et al (6 to <36 mo)	450	2000–2002, Europe	A/H1N1 No influenza illness	A/H3N2 A/H3N2	7/39 (17.9%) 92/398 (23.1%)	0.78 (0.38, 1.46)
Tam et al (12 to <36 mo)	494	2000–2002, Asia	A/H1N1 No influenza illness	A/H3N2 A/H3N2	3/40 (7.5%) 40/410 (9.8%)	0.77 (0.24, 2.14)
Bracco et al (6 to <36 mo)	342	2001–2002, South America	A/H3N2 No influenza illness	A/H1N1 A/H1N1	7/55 (12.7%) 11/280 (3.9%)	3.24 (1.33, 7.73)
Pooled	1286	NA	Influenza A No influenza illness	Alternate Subtype Influenza A Alternate Subtype Influenza A	17/134 (12.7%) 143/1088 (13.1%)	0.97 (0.60, 1.52)
<i>Heterotypic Immunity</i>						
Vesikari et al (6 to <36 mo)	450	2000–2002, Europe	A/H1N1 No influenza illness	B B	4/39 (10.3%) 30/398 (7.5%)	1.36 (0.52, 3.40)
Tam et al (12 to <36 mo)	494	2000–2002, Asia	A/H1N1 No influenza illness	B B	2/40 (5.0%) 11/410 (2.7%)	1.86 (0.38, 7.00)
Pooled	944	NA	A/H1N1 No influenza illness	B B	6/79 (7.6%) 41/808 (5.1%)	1.50 (0.66, 3.27)
<i>Homosubtypic Immunity</i>						
Tam et al* (12 to <36 mo)	494	2000–2002, Asia	A/H1N1 No influenza illness	A/H1N1 A/H1N1	0/40 (0%) 4/410 (1.0%)	0.0 (0.00, 9.66)
Belshe et al† (15 to <72 mo)	441	1996–1998, United States	A/H3N2 No influenza illness	A/H3N2 A/H3N2	1/52 (1.9%) 52/363 (14.3%)	0.13 (0.01, 0.72)
Pooled	891	NA	Influenza A No influenza illness	Same Subtype Influenza A Same Subtype Influenza A	1/92 (1.1%) 56/773 (7.2%)	0.15 (0.01, 0.82)

RR=relative risk.

*A/H1N1 strains in years 1 and 2 were antigenically similar (A/New Caledonia/20/99-like).

†A/H3N2 strains in years 1 and 2 were antigenically distinct (A/Wuhan/359/95-like in year 1; A/Sydney/5/97-like in year 2).